genOway Société anonyme (ALGEN.PA)
EUR 2.8
(0.7%)
EUR 2.8
(0.7%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 5.51 Million EUR | -23.35% |
| 2022 | 7.2 Million EUR | -19.95% |
| 2021 | 8.99 Million EUR | -10.18% |
| 2020 | 10.01 Million EUR | 90.22% |
| 2019 | 5.26 Million EUR | 12.99% |
| 2018 | 4.65 Million EUR | 24.86% |
| 2017 | 3.73 Million EUR | 0.0% |
| 2016 | - EUR | 0.0% |
| 2015 | - EUR | 0.0% |
| 2014 | - EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| 2011 | - EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q4 | 5.51 Million EUR | 0.0% |
| 2023 Q2 | 6.04 Million EUR | 0.0% |
| 2023 FY | 5.51 Million EUR | -23.35% |
| 2022 Q4 | 7.2 Million EUR | 0.0% |
| 2022 Q2 | 8.33 Million EUR | 0.0% |
| 2022 FY | 7.2 Million EUR | -19.95% |
| 2021 Q2 | 7.95 Million EUR | 0.0% |
| 2021 FY | 8.99 Million EUR | -10.18% |
| 2021 Q4 | 8.99 Million EUR | 0.0% |
| 2020 Q2 | 10.26 Million EUR | 0.0% |
| 2020 Q4 | 10.01 Million EUR | 0.0% |
| 2020 FY | 10.01 Million EUR | 90.22% |
| 2019 Q2 | 5.63 Million EUR | 0.0% |
| 2019 Q4 | 5.26 Million EUR | 0.0% |
| 2019 FY | 5.26 Million EUR | 12.99% |
| 2018 Q2 | 4.5 Million EUR | 0.0% |
| 2018 FY | 4.65 Million EUR | 24.86% |
| 2018 Q4 | 4.31 Million EUR | 0.0% |
| 2017 Q4 | 3.73 Million EUR | 0.0% |
| 2017 Q2 | 3.4 Million EUR | 0.0% |
| 2017 FY | 3.73 Million EUR | 0.0% |
| 2016 Q4 | - EUR | 0.0% |
| 2016 Q2 | - EUR | 0.0% |
| 2016 FY | - EUR | 0.0% |
| 2015 FY | - EUR | 0.0% |
| 2015 Q2 | - EUR | 0.0% |
| 2015 Q4 | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2014 Q2 | - EUR | 0.0% |
| 2014 FY | - EUR | 0.0% |
| 2013 Q2 | - EUR | 0.0% |
| 2013 Q4 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q4 | - EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -401.299% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 87.652% |
| Adocia SA | 4.54 Million EUR | -21.571% |
| Aelis Farma SA | 2.04 Million EUR | -169.497% |
| Biophytis S.A. | 3.11 Million EUR | -77.412% |
| Advicenne S.A. | 15.89 Million EUR | 65.279% |
| IntegraGen SA | 642.28 Thousand EUR | -759.329% |
| Medesis Pharma S.A. | 1.2 Million EUR | -359.942% |
| Neovacs S.A. | 650 Thousand EUR | -749.123% |
| NFL Biosciences SA | 39.2 Thousand EUR | -13978.772% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -26.691% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -181.55% |
| Sensorion SA | 1.24 Million EUR | -344.778% |
| Theranexus Société Anonyme | 2.46 Million EUR | -124.296% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -41.593% |
| TheraVet SA | 1 Million EUR | -451.6% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 20.08% |
| DBV Technologies S.A. | 4.52 Million USD | -21.947% |
| Genfit S.A. | 62.25 Million EUR | 91.134% |
| GeNeuro SA | 6.49 Million EUR | 14.987% |
| Innate Pharma S.A. | 30.6 Million EUR | 81.967% |
| Inventiva S.A. | 25.61 Million EUR | 78.454% |
| MaaT Pharma SA | 5.42 Million EUR | -1.738% |
| MedinCell S.A. | 52.8 Million EUR | 89.547% |
| Nanobiotix S.A. | 41.66 Million EUR | 86.752% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 84.456% |
| Poxel S.A. | 40.14 Million EUR | 86.251% |
| GenSight Biologics S.A. | 1.04 Million EUR | -426.651% |
| Transgene SA | 17 Thousand EUR | -32366.476% |
| Valneva SE | 132.76 Million EUR | 95.843% |